RESUMO
Many forms of the toxic effects produced by dioxins and related chemicals take place following activation of the aryl hydrocarbon receptor (AHR). Our previous studies have demonstrated that treating pregnant rats with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a highly toxic dioxin, attenuates the pituitary expression of gonadotropins to reduce testicular steroidogenesis during the fetal stage, resulting in the impairment of sexually-dimorphic behaviors after the offspring reach maturity. To investigate the contribution of AHR to these disorders, we examined the effects of TCDD on AHR-knockout (AHR-KO) Wistar rats. When pregnant AHR-heterozygous rats were given an oral dose of 1⯵g/kg TCDD at gestational day (GD) 15, TCDD reduced the expression of pituitary gonadotropins and testicular steroidogenic proteins in male wild-type fetuses at GD20 without affecting body weight, sex ratio and litter size. However, the same defect did not occur in AHR-KO fetuses. Further, fetal exposure to TCDD impaired the activity of masculine sexual behavior after reaching adulthood only in the wild-type offspring. Also, in female offspring, not only the fetal gonadotropins production but also sexual dimorphism, such as saccharin preference, after growing up were suppressed by TCDD only in the wild-type. Interestingly, in the absence of TCDD, deleting AHR reduced masculine sexual behavior, as well as fetal steroidogenesis of the pituitary-gonadal axis. These results provide novel evidence that 1) AHR is required for TCDD-produced defects in sexually-dimorphic behaviors of the offspring, and 2) AHR signaling plays a role in gonadotropin synthesis during the developmental stage to acquire sexual dimorphism after reaching adulthood.
Assuntos
Hipófise/metabolismo , Dibenzodioxinas Policloradas/toxicidade , Efeitos Tardios da Exposição Pré-Natal/metabolismo , Receptores de Hidrocarboneto Arílico/deficiência , Caracteres Sexuais , Testículo/metabolismo , Animais , Dioxinas/toxicidade , Poluentes Ambientais , Feminino , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gonadotropinas Hipofisárias/metabolismo , Locomoção/efeitos dos fármacos , Locomoção/fisiologia , Masculino , Hipófise/efeitos dos fármacos , Gravidez , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Ratos , Ratos Wistar , Receptores de Hidrocarboneto Arílico/agonistas , Testículo/efeitos dos fármacosRESUMO
Apelin is an adipose tissue derived peptidergic hormone. In this study, 40 male Sprague-Dawley rats were used (four groups; n = 10). Apelin-13 at three different dosages (1, 5 and 50 µg/kg) was given intraperitoneally while the control group received vehicle the same route for a period of 14 days. In results, apelin-13 caused significant decreases in serum testosterone, luteinizing hormone and follicle-stimulating hormone levels (p < 0.05). Administration of apelin-13 significantly increased body weights, food intake, serum low-density lipoprotein and total cholesterol levels (p < 0.05), but caused significant decreases in high-density lipoprotein levels (p < 0.05). Serum glucose and triglyceride levels were not significantly altered by apelin-13 administration. Significant decreases in both uncoupling protein (UCP)-1 levels in the white and brown adipose tissues and UCP-3 levels in the biceps muscle (p < 0.05) were noted. The findings of the study suggest that apelin-13 may not only lead to obesity by increasing body weight but also cause infertility by suppressing reproductive hormones.
Assuntos
Ingestão de Energia/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Comportamento Alimentar/efeitos dos fármacos , Hipercolesterolemia/induzido quimicamente , Infertilidade Masculina/induzido quimicamente , Peptídeos e Proteínas de Sinalização Intercelular/toxicidade , Sobrepeso/induzido quimicamente , Tecido Adiposo Marrom/efeitos dos fármacos , Tecido Adiposo Marrom/metabolismo , Tecido Adiposo Branco/efeitos dos fármacos , Tecido Adiposo Branco/metabolismo , Animais , Relação Dose-Resposta a Droga , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gonadotropinas Hipofisárias/sangue , Hipercolesterolemia/sangue , Hipercolesterolemia/metabolismo , Infertilidade Masculina/sangue , Infertilidade Masculina/metabolismo , Injeções Intraperitoneais , Masculino , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Sobrepeso/sangue , Sobrepeso/metabolismo , Distribuição Aleatória , Ratos Sprague-Dawley , Testosterona/antagonistas & inibidores , Testosterona/sangue , Testes de Toxicidade Crônica , Proteína Desacopladora 1/antagonistas & inibidores , Proteína Desacopladora 1/genética , Proteína Desacopladora 1/metabolismo , Proteína Desacopladora 3/antagonistas & inibidores , Proteína Desacopladora 3/genética , Proteína Desacopladora 3/metabolismo , Aumento de Peso/efeitos dos fármacosRESUMO
In various vertebrate species, dopamine (DA) exerts an inhibitory action on reproduction. In the European eel, DA plays a pivotal role in the inhibitory control of gonadotroph function and the blockade of puberty. In vivo studies have suggested that this effect is mediated by receptors pharmacologically related to the D2 family. In the European eel, two distinct D2 receptor (D2-R) paralogous genes have been identified (D2A-R and D2B-R) and both were shown to be expressed in the pituitary. We investigated the potential role of each paralogue in the control of gonadotroph function in this species. Eel recombinant D2A-R or D2B-R were expressed in HEK 293 cells, with a universal Gα subunit, and receptor activation was followed by inositol phosphate production. Recombinant D2-Rs exhibited a comparable affinity for DA, although they had differential affinities for mammalian D2-R agonists and antagonists, supporting subtle structure/activity differences. Furthermore, using eel pituitary cell primary cultures, the expression by gonadotroph cells of both native eel D2-R paralogues was examined by in situ hybridisation of D2A-R or D2B-R transcripts, coupled with immunofluorescence of luteinising hormone (LH)ß or follicle-stimulating (FSH)ß. LH and to a lesser extent, FSH cells expressed both D2-R transcripts but with a clear predominance of D2B-R. Notably, D2B-R transcripts were detected for the majority of LH cells. Accordingly, using these cultures, we showed that DA potently inhibited basal and testosterone-stimulated LHß expression and less potently basal and activin-stimulated FSHß expression. We also tested some D2-R antagonists, aiming to select the most adequate one to be used in innovative protocols for induction of eel sexual maturation. We identified eticlopride as the most potent inhibitor of DA action on basal and stimulated LH expression in vitro. Our data suggest a differential functionalisation of the duplicated receptor genes and demonstrate that mainly D2B-R is involved in the dopaminergic inhibitory control of eel gonadotroph function.
Assuntos
Enguias/metabolismo , Proteínas de Peixes/metabolismo , Subunidade beta do Hormônio Folículoestimulante/metabolismo , Gonadotropinas Hipofisárias/metabolismo , Hormônio Luteinizante Subunidade beta/metabolismo , Receptores de Dopamina D2/metabolismo , Animais , Dopamina/administração & dosagem , Antagonistas dos Receptores de Dopamina D2/administração & dosagem , Feminino , Subunidades alfa de Proteínas de Ligação ao GTP/metabolismo , Gonadotropinas Hipofisárias/antagonistas & inibidores , Células HEK293 , Humanos , RNA Mensageiro/metabolismo , Receptores de Dopamina D2/genéticaRESUMO
Until few years ago, Klinefelter syndrome with a homogenous 47,XXY karyotype was considered a model of absolute male sterility. We will discuss first the potential fertility following Testicular Sperm Injection, then the physiopathology of spermatogenic failure and the origin of focal spermatogenesis and risk of aneuploidy in offspring, and third the advantage of searching spermatozoa earlier instead of adult age. The rate of positive sperm extraction seems to be better for younger patients. During childhood, there is a low rate of spermatogonia. The spermagonia, which completes the spermatogenesis, seems resulting from a rare clone of 46,XY gonia, having lost their extra X chromosome. Several arguments suggest that this focal spermatogenesis decreases with age. In addition, androgen treatment, frequently prescribed in case of Klinefelter syndrome, carries a risk of decreasing focal spermatogenesis by lowering gonadotropins. The question arises if it is necessary to expect the sperm cryopreservation before introducing androgen treatment. Further studies are necessary to determine the best age of sperm retrieval in case of Klinefelter syndrome.
Assuntos
Infertilidade Masculina/terapia , Síndrome de Klinefelter/complicações , Injeções de Esperma Intracitoplásmicas/métodos , Adolescente , Adulto , Androgênios/efeitos adversos , Androgênios/farmacologia , Androgênios/uso terapêutico , Criopreservação , Feminino , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gonadotropinas Hipofisárias/fisiologia , Terapia de Reposição Hormonal , Humanos , Infertilidade Masculina/complicações , Síndrome de Klinefelter/patologia , Síndrome de Klinefelter/fisiopatologia , Masculino , Gravidez , Taxa de Gravidez , Risco , Preservação do Sêmen , Recuperação Espermática , Espermatogênese/efeitos dos fármacos , Espermatogênese/fisiologia , Espermatogônias/patologiaRESUMO
We evaluated the effects of opiate consumption on semen quality, sperm function, seminal plasma antioxidant capacity, and sperm DNA integrity. A total of 142 opiate addict men (group 1) were enrolled in the study and 146 healthy age matched male volunteers (group 2) served as controls. Two semen analyses were performed in all participants. Sperm chromatin structure assay (SCSA) was used to identify sperm DNA integrity. The mean±SD sperm concentration in opiate users and in control subjects was 22.2±4.4 and 66.3±8.3 million per ml, respectively (P=0.002). A significant increase in the amount of fragmented DNA was found in opiate consumers compared with that in controls (36.4±3.8% vs. 27.1±2.4%, P=0.004). Significantly decreased levels of catalase-like and superoxide dismutase-like (SOD) activity were observed in group 1 compared with group 2. Opiate consumption has significant adverse effects on semen quality. In cases of unexplained infertility in men, opium consumption should be considered as a possible factor.
Assuntos
Analgésicos Opioides/toxicidade , Dano ao DNA , Infertilidade Masculina/etiologia , Transtornos Relacionados ao Uso de Opioides/fisiopatologia , Oxirredutases/antagonistas & inibidores , Sêmen/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Reação Acrossômica/efeitos dos fármacos , Adulto , Analgésicos Opioides/farmacocinética , Analgésicos Opioides/urina , Estudos de Casos e Controles , Cromatina/química , Cromatina/efeitos dos fármacos , Manual Diagnóstico e Estatístico de Transtornos Mentais , Hormônios Esteroides Gonadais/antagonistas & inibidores , Hormônios Esteroides Gonadais/sangue , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gonadotropinas Hipofisárias/sangue , Alucinógenos/farmacocinética , Alucinógenos/toxicidade , Alucinógenos/urina , Humanos , Infertilidade Masculina/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Transtornos Relacionados ao Uso de Opioides/sangue , Transtornos Relacionados ao Uso de Opioides/urina , Oxirredutases/metabolismo , Sêmen/química , Sêmen/enzimologia , Detecção do Abuso de Substâncias , Adulto JovemRESUMO
Sheep are seasonal breeders, experiencing an annual period of reproductive quiescence in response to increased photoperiod during the late-winter into spring and renaissance during the late summer. The nonbreeding (anestrous) season is characterized by a reduction in the pulsatile secretion of GnRH from the brain, in part because of an increase in negative feedback activity of estrogen. Neuronal populations in the hypothalamus that produce kisspeptin and gonadotropin-inhibitory hormone (GnIH) appear to be important for the seasonal shift in reproductive activity, and the former are also mandatory for puberty onset. Kisspeptin cells in the arcuate nucleus (ARC) and preoptic area appear to regulate GnRH neurons and transmit sex-steroid feedback signals to these neurons. Moreover, kisspeptin expression in the ARC is markedly up-regulated at the onset of the breeding season, as too are the number of kisspeptin fibers in close apposition to GnRH neurons. The lower levels of kisspeptin seen during the nonbreeding season can be "corrected" by infusion of kisspeptin, which causes ovulation in seasonally acyclic females. The role of GnIH is less clear, but mounting evidence supports a role for this neuropeptide in the inhibitory regulation of both GnRH secretion and gonadotropin release from the pituitary gland. Contrary to kisspeptin, GnIH expression is markedly reduced at the onset of the breeding season. In addition, the number of GnIH fibers in close apposition to GnRH neurons also decreases during this time. Importantly, exogenous GnIH treatment can block both the pulsatile release of LH and the preovulatory LH surge during the breeding season. In summary, it is most likely the integrated function of both these neuropeptide systems that modulate the annual shift in photoperiod to a physiological change in fertility.
Assuntos
Kisspeptinas/fisiologia , Neuropeptídeos/fisiologia , Reprodução/fisiologia , Estações do Ano , Ovinos/fisiologia , Animais , Cruzamento , Retroalimentação Fisiológica , Feminino , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Hormônio Liberador de Gonadotropina/metabolismo , Hormônio Liberador de Gonadotropina/fisiologia , Gonadotropinas Hipofisárias/antagonistas & inibidores , Antagonistas de Hormônios , Hipotálamo/fisiologia , Kisspeptinas/genética , Hormônio Luteinizante/metabolismo , Fotoperíodo , Hipófise/fisiologiaRESUMO
Methods to restore fertility of men and women sterilized by medical treatments and environmental toxicant exposures are under investigation. Rendering spermatogenesis and ovarian follicular development kinetically quiescent by suppression of gonadotropins has been proposed to protect them from damage by cytotoxic therapy. Although the method fails to protect the fertility of male mice and monkeys, gonadotropin and testosterone suppression in rats before or after cytotoxic therapy do enhance the recovery of spermatogenesis. However, the mechanism involves not the induction of quiescence but rather the reversal, by suppression of testosterone, of a block in differentiation of surviving spermatogonia caused by damage to the somatic environment. In men, only one of eight clinical trials was successful in protecting or restoring spermatogenesis after cytotoxic therapy. In women, protection of primordial follicles in several species from damage by cytotoxic agents using GnRH analogs has been claimed; however, only two studies in mice appear convincing. The protection cannot involve the induction of quiescence in the already dormant primordial follicle but may involve direct effects of GnRH analogs or indirect effects of gonadotropin suppression on the whole ovary. Although numerous studies in female patients undergoing chemotherapy indicate that GnRH analogs might be protective of ovarian function, none of the studies showing protection were prospective randomized clinical trials and thus they are inconclusive. Considering interspecies differences and similarities in the gonadal sensitivity to cytotoxic agents and hormones, mechanistic studies are needed to identify the specific beneficial effects of hormonal suppression in select animal models that may be applicable to humans.
Assuntos
Gonadotropinas Hipofisárias/antagonistas & inibidores , Infertilidade Feminina/prevenção & controle , Infertilidade Masculina/prevenção & controle , Animais , Ensaios Clínicos como Assunto , Feminino , Hormônio Liberador de Gonadotropina/agonistas , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Infertilidade Feminina/etiologia , Infertilidade Masculina/etiologia , Masculino , Modelos Animais , Neoplasias/tratamento farmacológico , Neoplasias/radioterapia , Folículo Ovariano , Ovário , Espermatozoides , Testosterona/antagonistas & inibidoresRESUMO
A significant amount of research has been focused on the relationship between hormones and Alzheimer's disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimer's disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimer's disease. This review provides information supporting the "gonadotropin hypothesis," puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimer's disease, and discusses potential therapeutic anti-gonadotropin compounds.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Gonadotropinas Hipofisárias/antagonistas & inibidores , Antagonistas de Hormônios/uso terapêutico , Doença de Alzheimer/sangue , Doença de Alzheimer/patologia , Progressão da Doença , Tratamento Farmacológico/métodos , Tratamento Farmacológico/tendências , Gonadotropinas Hipofisárias/sangue , Humanos , Modelos BiológicosRESUMO
Based on epidemiological and observational studies, estrogen and hormone-replacement therapy were until recently viewed as major factors in the prevention of Alzheimer's disease (AD). However, a recent randomized clinical trial revealed that hormone replacement therapy using estrogen plus progestin may actually exacerbate the incidence of dementia when administered to elderly women. These contradictory reports have cast grave doubt on the role of estrogen in disease pathogenesis and led us to consider an alternate hypothesis that would be consistent with both observations. Specifically, we suspect that hormones of the hypothalamic pituitary gonadal axis such as gonadotropins, that are regulated by estrogen (or in males by testosterone), are involved in the pathogenesis of Alzheimer's disease. One such gonadotropin, luteinizing hormone (LH), is significantly elevated in both the sera and brain tissue of patients with AD and leads to an increased production of amyloid-beta. Importantly, a key role in disease pathogenesis is further supported by the fact that the distribution of neuronal receptors for LH parallels those populations of neurons that degenerate during the course of the disease. That gonadotropins, not estrogen nor testosterone, mediate disease pathogenesis has led to a paradigm shift, not only for the treatment of AD but a wide variety of other age-related diseases. Therefore, the effects of agents that abolish LH, such as leuprolide acetate, which are currently being evaluated in Phase II clinical trials for the treatment of AD, are eagerly anticipated.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Gonadotropinas Hipofisárias/metabolismo , Sistema Hipotálamo-Hipofisário/fisiopatologia , Leuprolida/farmacologia , Doença de Alzheimer/fisiopatologia , Peptídeos beta-Amiloides/biossíntese , Animais , Estrogênios/efeitos adversos , Feminino , Gonadotropinas Hipofisárias/antagonistas & inibidores , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Leuprolida/uso terapêutico , Hormônio Luteinizante/antagonistas & inibidores , Hormônio Luteinizante/metabolismo , Masculino , Receptores do LH/metabolismo , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologiaRESUMO
The aim of this study was to verify the effect of goserelin, a GnRH agonist, in women with post-menopausal virilization. Six patients with post-menopausal virilization and increase in 17-hydroxyprogesterone (17-OHP), total (TT) and free testosterone (FT) levels underwent single subcutaneous administration of goserelin, 3.6 mg. Serum 17-OHP, TT, FT, LH, FSH, E2, delta4 and 3alpha-andro-stanediol glucuronide levels were measured before and 4, 8 and 18 days after goserelin administration. Goserelin administration was followed by progressive inhibition of FSH and LH, which fell to premenopausal levels on day 18, and progressive normalization of androgen parameters. The low E2 levels recorded at baseline were further reduced by goserelin administration. Four patients then underwent ovariectomy while in two patients, rejecting surgical treatment, goserelin treatment was protracted up to 6 and 12 months, respectively, with remission of hyperandrogenism. This study shows that in post-menopausal patients with virilization GnRH agonist allows to confirm the diagnosis of gonadotropin-dependent ovarian hyperandrogenism: its administration induces inhibition of gonadotropin levels, normalization of androgen parameters, and remission of virilization when the treatment is protracted in patients waiting for surgery.
Assuntos
Antagonistas de Androgênios/uso terapêutico , Gonadotropinas/antagonistas & inibidores , Gosserrelina/administração & dosagem , Hiperandrogenismo/tratamento farmacológico , Pós-Menopausa , Hormônio Adrenocorticotrópico , Idoso , Esquema de Medicação , Feminino , Gonadotropinas Hipofisárias/antagonistas & inibidores , Humanos , Hiperandrogenismo/complicações , Hiperandrogenismo/diagnóstico , Pessoa de Meia-Idade , Indução de Remissão , Virilismo/etiologiaRESUMO
Targeted gene disruption has produced knockout mice lacking the orphan nuclear receptor steroidogenic factor 1 (SF-1). These SF-1 knockout mice lacked adrenal glands and gonads, resulting in adrenocortical insufficiency and sex reversal of their internal and external genitalia. They also had impaired expression of pituitary gonadotropins and agenesis of the ventromedial hypothalamic nucleus (VMH), confirming roles of SF-1 at multiple levels of the hypothalamic-pituitary-steroidogenic tissue axis. Using the Cre-loxP system, we now have generated mice in which SF-1 is inactivated selectively in the anterior pituitary. These pituitary-specific SF-1 knockout mice were sterile and failed to exhibit sexual maturation. Histologically, their gonads were markedly hypoplastic, weighing only approximately 5% of the gonads of wild-type mice. Consistent with an important role of SF-1 in gonadotropes, there were no cells in the pituitary gland that expressed either follicle-stimulating hormone (FSH) or luteinizing hormone (LH). These pituitary-specific SF-1 knockout mice are a novel genetic model of hypogonadotropic hypogonadism and establish essential roles of SF-1 in gonadotropin expression.
Assuntos
Proteínas de Ligação a DNA/fisiologia , Gonadotropinas Hipofisárias/biossíntese , Sistema Hipotálamo-Hipofisário/fisiologia , Sistema Hipófise-Suprarrenal/fisiologia , Fatores de Transcrição/fisiologia , Glândulas Suprarrenais/anormalidades , Animais , Proteínas de Ligação a DNA/genética , Proteínas de Ligação a DNA/farmacologia , Feminino , Hormônio Foliculoestimulante/deficiência , Fatores de Transcrição Fushi Tarazu , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gônadas/anormalidades , Proteínas de Homeodomínio , Hormônio Luteinizante/deficiência , Masculino , Camundongos , Camundongos Knockout , Receptores Citoplasmáticos e Nucleares , Fator Esteroidogênico 1 , Fatores de Transcrição/genética , Fatores de Transcrição/farmacologiaRESUMO
The hypothalamic gonadotrophin-releasing hormone (GnRH) stimulates synthesis and secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the gonadotrophic cells of the pituitary. The mechanisms of action of GnRH antagonists and of agonists is completely different. Due tot competitive blockage of GnRH receptors by antagonist administration, LH (and to a lesser extent FSH) levels drop rapidly. Moreover pituitary function normalizes immediately following cessation of medication. The direct and rapid action of GnRH antagonists, the dose dependent suppression of LH and FSH and the rapid restoration of hypophyseal function after cessation of the use of antagonists may shorten and simplify in-vitro fertilization, with less chance of side effects or complications. Further studies are required to decide whether antagonists can usefully be applied for other gynecological indications such as the polycystic ovary syndrome. The possibilities of profitable long term treatment will increase considerably if it proves possible to develop a sustained action formulation.
Assuntos
Fármacos para a Fertilidade Feminina/uso terapêutico , Fertilização in vitro/métodos , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Gonadotropinas Hipofisárias/metabolismo , Indução da Ovulação/métodos , Relação Dose-Resposta a Droga , Feminino , Fármacos para a Fertilidade Feminina/farmacologia , Hormônio Foliculoestimulante/metabolismo , Hormônio Liberador de Gonadotropina/análogos & derivados , Gonadotropinas Hipofisárias/antagonistas & inibidores , Humanos , Hormônio Luteinizante/metabolismo , Hipófise/efeitos dos fármacosRESUMO
The hormonal approach to male contraception is based on the suppression of gonadotrophin secretion with secondary suppression of spermatogenesis. This can be achieved by administration of testosterone or other androgen alone, but combined administration with a progestogen or GnRH analogue allows the dose of testosterone to be reduced to physiological replacement doses. This approach has been investigated for many years but without identification of a regimen which results in sufficient suppression of spermatogenesis to provide ensured contraception in all men, safely and conveniently. The reasons for this are discussed, and recent developments towards a regimen that fulfills all these criteria are described. Crucial to development of any new product is that it will be used: surveys of both men and women indicate firmly positive attitudes towards a 'male pill'. There are, therefore, grounds for cautious optimism that the next decade may see the introduction of the first novel male contraceptive for several hundred years.
Assuntos
Antiespermatogênicos/administração & dosagem , Gonadotropinas Hipofisárias/antagonistas & inibidores , Nandrolona/análogos & derivados , Testosterona/análogos & derivados , Testosterona/administração & dosagem , Acne Vulgar/induzido quimicamente , Implantes de Medicamento , Conhecimentos, Atitudes e Prática em Saúde , Hematócrito , Hemoglobinas/metabolismo , Terapia de Reposição Hormonal , Humanos , Masculino , Nandrolona/administração & dosagem , Nandrolona/química , Oligospermia/induzido quimicamente , Testosterona/efeitos adversos , Testosterona/química , Aumento de PesoRESUMO
The inhibitory effect of inflammation and endotoxins on the secretion of reproductive hormones from the hypothalamo-pituitary axis is well documented. A comparison of the luteinizing hormone (LH) suppressing effects of several pro-inflammatory cytokines revealed that centrally administered IL-1 beta was the most potent inhibitor of pituitary LH secretion; interleukin (IL)-1 alpha and tumor necrosis factor (TNF) alpha were relatively less effective, whereas IL-6 was ineffective. This order of potency suggested that the anti-gonadotropic effects of an immune challenge are most likely attributable to the action of centrally released IL-1 beta, and this was supported by the demonstration that IL-1 beta suppressed hypothalamic luteinizing hormone releasing hormone (LHRH) release. We used a multifaceted approach to identify the afferent signals in the brain that convey immune messages to hypothalamic LHRH neurons. Pharmacological studies with specific antagonists of opioid receptor subtypes demonstrated that activation of the mu 1 receptor subtype was required to transmit the cytokine signal. Furthermore, icv IL-1 beta upregulated hypothalamic POMC mRNA and increased the concentration and release of beta-endorphin, the primary ligand of mu 1 receptors. We have obtained evidence that IL-1 beta also enhanced the gene expression and concentration of tachykinins, a family of nociceptive neuropeptides in the hypothalamus. Blockade of tachykinergic NK2 receptors attenuated IL-1 beta induced inhibition of LH secretion. Collectively, these results demonstrate that IL-1 beta, generated centrally in response to inflammation, upregulates the opioid and tachykinin peptides in the hypothalamus. These two groups of neuropeptides are critically involved in relaying the cytokine signal to neuroendocrine neurons and causing the suppression of hypothalamic LHRH and pituitary LH release.
Assuntos
Citocinas/farmacologia , Gonadotropinas Hipofisárias/antagonistas & inibidores , Hipotálamo/metabolismo , Neuropeptídeos/fisiologia , Animais , Citocinas/metabolismo , Endotoxinas/farmacologia , Feminino , Regulação da Expressão Gênica , Hormônio Liberador de Gonadotropina/metabolismo , Gonadotropinas Hipofisárias/metabolismo , Humanos , Sistema Hipotálamo-Hipofisário/imunologia , Sistema Hipotálamo-Hipofisário/fisiologia , Interleucina-1/metabolismo , Interleucina-1/farmacologia , Hormônio Luteinizante/sangue , Hormônio Luteinizante/metabolismo , Masculino , Sistema Hipófise-Suprarrenal/imunologia , Sistema Hipófise-Suprarrenal/fisiologia , Ratos , Receptores da Neurocinina-2/fisiologia , Receptores Opioides mu/fisiologiaRESUMO
La presente revisión tiene como objeto describir las características químicas y farmacológicas de los análogos de GnRh y las indicaciones actuales de sus uso en ginecología. Se realiza una revisión crítica del uso de análogos de GnRH en: Anticoncepción, Reproducción Asistida, Miomatosis Uterina, Endometriosis, Poliquistosis ovárica, Pubertad Precoz, Síndrome de Tensión Premenstrual y Cáncer de mama.
Assuntos
Gonadotropinas Hipofisárias/análise , Gonadotropinas Hipofisárias/antagonistas & inibidores , Ginecologia , Hormônios Liberadores de Hormônios Hipofisários/análise , FarmacologiaRESUMO
Male rainbow trout were treated with salmon gonadotropic hormone (GTH) at different stages of the circannual reproductive cycle; spawning fish were also treated with an antiserum against salmon GTH. Injection of GTH led to a several-fold increase of plasma sex steroid levels during spermatogenesis and in the spawning season but was without effect at early stages of testicular development. GTH neutralization during the spawning season was followed by a several-fold decrease of plasma sex steroid levels. During spermatogenesis and in the spawning season, both treatment regimes resulted in an increased sensitivity of testicular explants in response to a subsequent stimulation of steroid secretion in vitro. This up-regulatory response may facilitate and maintain the high sex steroid plasma levels observed during the spawning season. It may also be necessary to allow for concomitant peak values of plasma GTH and sex steroids in the spawning season, a situation difficult to understand within the negative feedback concept. The adaptive capacities of the testicular steroidogenic system indicate that it is not only an effector site for GTH but also an active part of the endocrine system controling reproduction.
Assuntos
Hormônios Esteroides Gonadais/sangue , Gonadotropinas Hipofisárias/farmacologia , Truta/sangue , Animais , Hormônios Esteroides Gonadais/metabolismo , Gonadotropinas Hipofisárias/antagonistas & inibidores , Técnicas In Vitro , Masculino , Reprodução/fisiologia , Salmão , Estações do Ano , Esteroides/sangue , Testículo/efeitos dos fármacos , Testículo/metabolismo , Truta/fisiologia , Regulação para CimaRESUMO
The results of treatment of 20 female patients with fibrocystic degeneration of the breast with danazol are discussed. Diagnosis was made with the aid of mammography. Danazol was administered in the dose of 200 mg twice a day for 2 months, followed by 100 mg thrice a day, and 100 mg twice a day for further 2 months. An improvement in the clinical symptoms, decrease in LH, FSH, estradiol and progesterone levels was produced by danazol. The drug did not change LH response to LH-RH stimulation while blockade of dopaminergic receptors with metoclopramide decreased PRL response.
Assuntos
Danazol/uso terapêutico , Doença da Mama Fibrocística/tratamento farmacológico , Pregnadienos/uso terapêutico , Adulto , Fenômenos Químicos , Química , Ensaios Clínicos como Assunto , Estradiol/sangue , Antagonistas de Estrogênios , Feminino , Doença da Mama Fibrocística/sangue , Gonadotropinas Hipofisárias/antagonistas & inibidores , Gonadotropinas Hipofisárias/sangue , Humanos , Pessoa de Meia-Idade , Progesterona/antagonistas & inibidores , Progesterona/sangue , Testosterona/sangueRESUMO
Ovulation induction in patients with hypergonadotropic premature ovarian failure is rarely successful. The authors have attempted to reproduce the results of recent case reports that suggest that ovulation and pregnancy can be successfully achieved when estrogen therapy precedes or coincides with ovarian stimulation with human menopausal gonadotropins (hMG). Fourteen patients with idiopathic premature ovarian failure underwent gonadotropin suppression and attempted ovulation induction with at least one of three regimens, which were as follows: 1) Group A: estrogen-induced suppression followed by hMG stimulation (n = 4). 2) Group B: estrogen-induced suppression followed by hMG stimulation with concomitant estrogen therapy (n = 10). 3) Group C: gonadotropin-releasing hormone agonist-induced gonadotropin suppression followed by concomitant hMG stimulation (n = 6). Despite complete gonadotropin suppression and high-dose hMG therapy in all three groups, ovulation occurred in only a single patient in group C. Pregnancy did not ensue. These data fail to corroborate previous case reports.
Assuntos
Gonadotropinas Hipofisárias/antagonistas & inibidores , Infertilidade Feminina/tratamento farmacológico , Menotropinas/uso terapêutico , Indução da Ovulação/métodos , Adulto , Quimioterapia Combinada , Estradiol/metabolismo , Estrogênios/uso terapêutico , Feminino , Hormônio Foliculoestimulante/metabolismo , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Medroxiprogesterona/análogos & derivados , Medroxiprogesterona/uso terapêutico , Acetato de MedroxiprogesteronaRESUMO
Bioassay of the pineal extract of F. pennanti was performed in immature female mice which was previously sensitized with human chorionic gonadotrophin. Reduction of ovarian and uterine weights indicated an antigonadotropic nature of the pineal gland of this animal.